2-pyridone derivatives as neutrophil elastase inhibitors and...

Details 2-pyridone derivatives as neutrophil elastase inhibitors and... 2-pyridone derivatives as neutrophil elastase inhibitors and...

2004-09-15

2011-11-22

Davis, Zinna Northington (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S256000

Reexamination Certificate

active

08063073

ABSTRACT:
There are provided novel compounds of formula (I), wherein R1, R2, R4, R5, G1, G2, L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.

REFERENCES:
patent: 4181658 (1980-01-01), Hitzel et al.
patent: 4186200 (1980-01-01), Kubo et al.
patent: 5441960 (1995-08-01), Bernstein et al.
patent: 5521179 (1996-05-01), Bernstein et al.
patent: 6028081 (2000-02-01), Sada et al.
patent: 6977266 (2005-12-01), Tada et al.
patent: 6979690 (2005-12-01), Gymer et al.
patent: 2004/0023973 (2004-02-01), Nagato et al.
patent: 2004/0082619 (2004-04-01), Tada et al.
patent: 2004/0235761 (2004-11-01), Furuta et al.
patent: 2005/0101590 (2005-05-01), Yasui et al.
patent: 2006/0035938 (2006-02-01), Bladh et al.
patent: 2006/0052411 (2006-03-01), Tada et al.
patent: 2006/0100249 (2006-05-01), Smith
patent: 2006/0211695 (2006-09-01), Borzilleri et al.
patent: 2006/0270666 (2006-11-01), Bladh et al.
patent: 2007/0010551 (2007-01-01), Bladh et al.
patent: 2007/0043036 (2007-02-01), Hansen et al.
patent: 2007/0203129 (2007-08-01), Andersson et al.
patent: 2007/0213323 (2007-09-01), Imogai et al.
patent: 2009/0105239 (2009-04-01), Brimert et al.
patent: 2009/0131483 (2009-05-01), Hansen et al.
patent: 2009/0131486 (2009-05-01), Hansen et al.
patent: 2009/0209555 (2009-08-01), Hansen et al.
patent: 2010/0216843 (2010-08-01), Briggner et al.
patent: 2010/0280048 (2010-11-01), Ainge et al.
patent: 2011/0003858 (2011-01-01), Bergstrom et al.
patent: 0008864 (1980-03-01), None
patent: 1300396 (2003-04-01), None
patent: 1357111 (2003-10-01), None
patent: 1465626 (2008-03-01), None
patent: 2383326 (2003-06-01), None
patent: 2383326 (2003-06-01), None
patent: 2392910 (2004-03-01), None
patent: 02152966 (1990-06-01), None
patent: WO 98/24780 (1998-06-01), None
patent: WO 01/96308 (2001-12-01), None
patent: WO 02/053543 (2002-07-01), None
patent: WO 02053543 (2002-11-01), None
patent: WO 03/047577 (2003-06-01), None
patent: WO-03/070277 (2003-08-01), None
patent: WO 2004/020410 (2004-03-01), None
patent: WO 2004/043924 (2004-05-01), None
patent: WO 2005/021509 (2005-03-01), None
patent: WO 2005/021512 (2005-03-01), None
patent: WO-2005/026123 (2005-03-01), None
patent: WO 2005/026124 (2005-03-01), None
patent: WO 2005/080372 (2005-09-01), None
patent: WO 2005/082864 (2005-09-01), None
patent: WO-2006/030032 (2006-03-01), None
patent: WO 2006/082412 (2006-08-01), None
patent: WO 2006/098683 (2006-09-01), None
patent: WO 2006/098684 (2006-09-01), None
patent: WO-2006/116713 (2006-11-01), None
patent: WO 2006/136857 (2006-12-01), None
patent: WO 2007/107706 (2007-09-01), None
patent: WO 2007/129060 (2007-11-01), None
patent: WO 2007/129962 (2007-11-01), None
patent: WO 2007/129963 (2007-11-01), None
patent: WO 2008/030158 (2008-03-01), None
patent: WO 2008/104752 (2008-09-01), None
patent: WO 2009/058076 (2009-05-01), None
patent: WO 2009/061271 (2009-05-01), None
patent: WO-2010/094964 (2010-08-01), None
Bauer and weber “Benzodiazepine mit psychotroper Wirkung, V 1.5-Benzodiazepin-trione und ihre Vorstufen” Justus Liebigs Annalen der Chemie 762: 73-82 (1972).
Harayama et al. “Hydrolysis products of flavins (isoalloxazines)” J. Chem. Soc. Perkin Trans 75-83 (1987).
Ohbayashi “Neutrophil elastase inhibitors as treatment for COPD” Expert Opin. Investig. Drugs 11(7):965-980 (2002).
Ohbayashi et al. “Novel neutrophil elastase inhibitors as a treatment for neutrophil-predominant inflammatory lung diseases” IDrugs 5(9):910-923 (2002).
Sato et al. “Neutrophil elastase and cancer” Surgical Oncology 15: 217-222 (2006).
Zeiher et al. “Neutrophil elastase and acute lung injury: Prospects for sivelestat and other neutrophil elastase inhibitors as therapeutics” Critical Care Medine 30(5): S281-S287 (2002).
Bauer and Weber “Benzodiazepines with psychotropic activity. V. 1,5-Benzodiazepinetriones and their precursors” Justus Liebigs Annalen der Chemie 762: 73-82 (1972) as abstracted by CAS on STN (File CAPLUS, Accession No. 1973:16148).
Beilstein Registry No. 7995731, Beilstein Institute for Organic Chemistry, XP002481053 & Khim. Geterotsikl. Soedin. vol. 34(1): 73-76 (1998).
Chughtai et al. “Potential Role of Inhibitors of Neutrophil Elastase in Treating Diseases of the Airway” Journal of Aerosol Medicine 17(4): 289-298 (2004).
Europ. Resp. Soc., Feb. 13, 2007, http://www.newtocopd.com/currentaffairsnews/list751—item17680.aspx, downloaded Jan. 16, 2008.
Friedman “Future Treatment Strategies for COPD” Clinical Cornerstone, COPD, 5(1):45-51 (2004).
Ohbayashi “Current synthetic inhibitors of human neutrophil elastase in 2005” Expert Opinion on Therapeutic Patents 15(7): 759-771 (2005).
Okayama et al. “Clinical effects of a neutrophil elastase inhibitor, sivelestat, in patients with acute respiratory distress syndrome” J. Anesth. 20:6-10 (2006).
Shimizu et al. “A mechanism of antigen-induced mucus production in nasal epithelium of sensitized rats. A comparison with lipopolysaccharide-induced mucus production” Am. J. Respir. Crit. Care Med. 161:1648-1654 (2000).
STN International, File CAPLUS, CAPLUS Accession No. 1990:611864, Document No. 113:211864, Otsuka Pharmaceutical Co., Ltd.: “4-Hydroxycarbostyrils as anti-inflammotory and antiallergy agents”, & JP, A2, 02152966 (1990).
STN International, File CAPLUS, CAPLUS Accession No. 1995:456529, Document No. 123:198678, Ukrainets, I.V. et al: “4-Hydroxy-2-quinolones. 23. N-(2-Thiazolyl)amides of 1-substituted 4-hydroxy-2-oxoquinoline-3-carboxylic acids—a new group of potential anti-inflammatory drugs”, & Khimiya Geterotsiklicheskikh Soedinenii 10: 1397-1399 (1994).
Ukrainets et al. “4-Hydroxy-2-quinolones. 23. N-(2-Thiazolyl)amides of 1-substituted 4-hydroxy-2-oxoquinoline-3-carboxylic acids—a new group of potential antiinflammatory drugs” Chemistry of Heterocyclic Compounds, A translation of Khimiya Geterotsiklicheskikh Soedinenii, 30(10): 1211-1213 (1994).
U.S. Appl. No. 12/895,995, filed Oct. 1, 2010.
Eistert, B., et al., “Synthese and Reaktionen substituierter Pyrrolin-2,3-dione mit Diazoalkanen,”Liebigs Ann. Chem. (1976), pp. 1023-1030.
Wright, J.L., et al., “A neutrophil elastase inhibitor reduces cigarette smoke-induced remodelling of lung vessels,”Eur Respir J(2003), vol. 22, pp. 77-81.
Office Action dated Apr. 9, 2008; U.S. Appl. No. 10/569,923 (Publication No. 2006/0270666).
Office Action dated Dec. 12, 2008; U.S. Appl. No. 10/569,923 (Publication No. 2006/0270666).
Restriction Requirement dated Feb. 28, 2008; U.S. Appl. No. 10/534,720 (Publication No. 2006/0035938).
Office Action dated Jun. 23, 2008; U.S. Appl. No. 10/534,720 (Publication No. 2006/0035938).
Office Action dated Jan. 2, 2009; U.S. Appl. No. 10/534,720 (Publication No. 2006/0035938).
Interview Summary dated Jul. 14, 2009; U.S. Appl. No. 10/534,720 (Publication No. 2006/0035938).
Office Action dated Sep. 29, 2008; U.S. Appl. No. 10/569,571 (Publication No. 2007/0010551).
Office Action dated Mar. 16, 2009; U.S. Appl. No. 10/569,571 (Publication No. 2007/0010551).
Interview Summary dated Sep. 28, 2009; U.S. Appl. No. 10/569,571 (Publication No. 2007/0010551).
Restriction Requirement dated Jan. 29, 2009; U.S. Appl. No. 10/572,640 (Publication No. 2007/0043036).
Interview Summary dated Aug. 4, 2009; U.S. Appl. No. 10/572,640 (Publication No. 2007/0043036).
Restriction Requirement dated Aug. 25, 2009; U.S. Appl. No. 12/299,879 (Publication No. 2009/0131486).
Office Action dated Dec. 28, 2009; U.S. Appl. No. 12/299,879 (Publication No. 2009/0131486).
Office Action dated Jun. 24, 2010; U.S. Appl. No. 12/299,879 (Publication No. 2009/0131486).
Notice of Allowance and Interview Summary dated Sep. 23, 2010; U.S.

Affiliated with

Also associated with

Rating

2-pyridone derivatives as neutrophil elastase inhibitors and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2-pyridone derivatives as neutrophil elastase inhibitors and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-pyridone derivatives as neutrophil elastase inhibitors and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4282559